AB1100 COVID-19 VACCINATION IN A REAL-LIFE SETTING OF A RHEUMATOLOGICAL OUTPATIENT CENTER

Background Since approvement of the first vaccines against COVID-19 in European 12/2020, a large vaccination (VAC) campaign was started. Patients with inflammatory diseases (ID) were graded as higher risk. Many our patients used possibility and got vaccinated. Until know, there is few knowledge about efficacy safety VAC ID. There are some reports less response ID (1). antibody (AB) studies ongoing but monitoring AB status not recommended by official recommendations (1,2). Nevertheless, testing commonly daily care outpatient centers (OC). Objectives To evaluate real life setting single rheumatological OC how many have been vaccinated COVID-19, these did develop search for possible explanations. Methods All consecutive routine follow up visits from 03/2021 to 12/2021 retrospectively evaluated if an (e.g. ELISA-tests) done ≥4 weeks after 2nd documented. tests classified levels (Ratio <0,8 negative, >0,8 Ratio < 4,5 low moderate, ≥ high level). The group without specified. Results N=1206 persons questioned. N=23/1206 (1.9%) refused VAC. N=1183/1206 (98.1%) N=984/1183 (83.2%) had ID, n=199/1183 (16.8%) healthy (HP). In n=608/1138 (51%) available. N=14/608 (20%) HP developed all one levels. 1 moderate level. n=595/1183 (50%) N=438/595 (74%) levels, n=126/595 (21%) n=30/595 (5%) no AB. Mean age any 69years (range 38-95). N=27/30 (90%) received ≥1 DMARD (disease modifying antirheumatic drug), n=3/30 treated DMARD, n=2/3 Prednisolone (P) instead. N=4/30 Rituximab (RTX), n=1/30 Abatacept (ABA), MMF (3g), Azathioprine combination P (55mg), n=15(50%) MTX alone or combination, n=24/30(80%) mg 1-55, mean 5,7). One 52y old patient receive nether nor P. N=3/30 both vaccinations Vaxzevira (V), n=25/30 (83,3%) Comirnaty (C), Spikevax, V, second C. patient, ABA has 2 doses A 4 months later reveal antibodies. This came down 5 complete died. Conclusion very number (98,1%) OC. (95%) VAC, independently which agent used. Otherwise, we must be aware small developing Unfortunately, too find significant risk factors (RF). But RF seems age, therapy RTX, line reported clinical Furthermore, see lower elderly who get could biased fact that, campaign, C C-VAC given 3 1st Retrospectively, this interval short. Thus now, 4-6 conclusion it still unclear, make effective will should pick out gap, since fatal course COVID-19-disease. booster 3rd change current state again, therefore revaluation necessary. References [1]Kroon FPB et al, Risk prognosis SARS-CoV-2 infection rheumatic musculoskeletal diseases: systematic literature review inform EULAR recommendations. ARD 07.12.2021 online first. [2] https://dgrh.de/Start/Wissenschaft/Forschung/COVID-19/Handlungsempfehlungen-der-DGRh-im-Rahmen-der-COVID-19-Pandemie.html Disclosure Interests Stephanie Gabriele Werner Speakers bureau: Abbvie, Janssen, Pfizer, Grant/research support from: Leander Moll: None declared, Antje Uhlenberg-Moll: Sabine Mettler: Hans-Eckhard Langer Medac, Bristol